Fragment-Based Drug Design and Identification of HJC0123 , a Novel Orally Bioavailable STAT3 Inhibitor for Cancer Therapy

European Journal of Medicinal Chemistry- France

doi 10.1016/j.ejmech.2013.01.023

Full Text

Abstract

Available in

Date

Authors

Publisher

Elsevier BV

Related search

Discovery of Potent Anticancer Agent HJC0416, an Orally Bioavailable Small Molecule Inhibitor of Signal Transducer and Activator of Transcription 3 (STAT3)

European Journal of Medicinal Chemistry
MedicineOrganic ChemistryDrug DiscoveryPharmacology
2014English

Discovery of Novel KRAS-PDE Inhibitors by Fragment-Based Drug Design

English

MK-8353: Discovery of an Orally Bioavailable Dual Mechanism ERK Inhibitor for Oncology

English

Targeting Constitutively-Activated STAT3 in Hypoxic Ovarian Cancer, Using a Novel STAT3 Inhibitor

Oncoscience
Cancer ResearchOncology
2014English

Discovery and Evaluation of BMS-708163, a Potent, Selective and Orally Bioavailable Γ-Secretase Inhibitor

ACS Medicinal Chemistry Letters
Organic ChemistryBiochemistryDrug Discovery
2010English

In Silico Approaches for Fragment-Based Drug Design

Yakugaku Zasshi
PharmacologyPharmaceutical Science
2010English

Design and Synthesis of Novel Isoquinoline-3-Nitriles as Orally Bioavailable Kv1.5 Antagonists for the Treatment of Atrial Fibrillation

English

In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2005English

A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets

Frontiers in Neurology
Neurology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy